<DOC>
	<DOC>NCT00819507</DOC>
	<brief_summary>The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.</brief_summary>
	<brief_title>VANOS Cream and Skin Barrier Function</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<criteria>Diagnosis of AD according to HanifinRajka criteria (see Appendix B) Age 12 years or older Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or Very Severe (See Appendix C) Must have failed to achieve adequate disease despite adequate topical or systemic therapy Must be a candidate, according to the principal investigator and standard of care, for a superpotent topical steroid course. Subjects that are candidates for superpotent topical steroids are defined as subjects whose disease is not adequately controlled with mediumpotency topical steroids or systemic therapy, including phototherapy. Active skin infection Hypersensitivity to any ingredients in Vanos cream Previous use of superpotent topical steroids within 2 weeks of starting study (Class I steroid).</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Skin barrier</keyword>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Effects on skin severity and barrier function</keyword>
</DOC>